siRNA vs. shRNA: similarities and differences
DD Rao, JS Vorhies, N Senzer, J Nemunaitis - Advanced drug delivery …, 2009 - Elsevier
RNA interference (RNAi) is a natural process through which expression of a targeted gene
can be knocked down with high specificity and selectivity. Using available technology and …
can be knocked down with high specificity and selectivity. Using available technology and …
[HTML][HTML] Ovarian cancer immunotherapy and personalized medicine
S Morand, M Devanaboyina, H Staats… - International Journal of …, 2021 - mdpi.com
Ovarian cancer response to immunotherapy is limited; however, the evaluation of
sensitive/resistant target treatment subpopulations based on stratification by tumor …
sensitive/resistant target treatment subpopulations based on stratification by tumor …
Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy
A Alqahtani, K Choucair, M Ashraf… - Future science …, 2019 - Future Science
Histone lysine acetylation is critical in regulating transcription. Dysregulation of this process
results in aberrant gene expression in various diseases, including cancer. The …
results in aberrant gene expression in various diseases, including cancer. The …
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or …
DH Johnson, L Fehrenbacher, WF Novotny… - Journal of Clinical …, 2004 - ascopubs.org
Purpose To investigate the efficacy and safety of bevacizumab plus carboplatin and
paclitaxel in patients with advanced or recurrent non-small-cell lung cancer. Patients and …
paclitaxel in patients with advanced or recurrent non-small-cell lung cancer. Patients and …
[PDF][PDF] Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate …
EJ Small, PF Schellhammer, CS Higano, CH Redfern… - J clin Oncol, 2006 - academia.edu
Placebo-Controlled Phase III Trial of Immunologic Therapy with Sipuleucel-T (APC8015) in
Patients with Metastatic, Asymptomatic Page 1 Placebo-Controlled Phase III Trial of Immunologic …
Patients with Metastatic, Asymptomatic Page 1 Placebo-Controlled Phase III Trial of Immunologic …
[PDF][PDF] Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
RH Collins Jr, O Shpilberg, WR Drobyski… - Journal of clinical …, 1997 - researchgate.net
Purpose: Recipients of allogeneic bone marrow transplants (BMTs) who have relapsed may
attain complete remissions when treated with transfusions of leukocytes obtained from the …
attain complete remissions when treated with transfusions of leukocytes obtained from the …
A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and …
ONYX-015 is an adenovirus with the E1B 55-kDa gene deleted, engineered to selectively
replicate in and lyse p53-deficient cancer cells while sparing normal cells. Although ONYX …
replicate in and lyse p53-deficient cancer cells while sparing normal cells. Although ONYX …
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies
PURPOSE: To assess the feasibility of administering OSI-774, to recommend a dose on a
protracted, continuous daily schedule, to characterize its pharmacokinetic behavior, and to …
protracted, continuous daily schedule, to characterize its pharmacokinetic behavior, and to …
[PDF][PDF] Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable …
NN Senzer, HL Kaufman, T Amatruda… - Journal of Clinical …, 2009 - academia.edu
Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding,
Second-Generation Oncolytic Herpesviru Page 1 Phase II Clinical Trial of a Granulocyte-Macrophage …
Second-Generation Oncolytic Herpesviru Page 1 Phase II Clinical Trial of a Granulocyte-Macrophage …
Integrated data from 2 randomized, double‐blind, placebo‐controlled, phase 3 trials of active cellular immunotherapy with sipuleucel‐T in advanced prostate cancer
CS Higano, PF Schellhammer, EJ Small… - … Journal of the …, 2009 - Wiley Online Library
BACKGROUND: Sipuleucel‐T is an investigational active cellular immunotherapy product
designed to stimulate an immune response against prostate cancer. The safety and efficacy …
designed to stimulate an immune response against prostate cancer. The safety and efficacy …